BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
After having toughed out for more than three years in the U.S., Sun Pharmaceutical Industries Ltd.'s flagship product Ilumya is continuously ramping-up sales, with Cequa also showing good traction.
This is slightly offset by generic competition in Absorica and difficulty in shifting prescriptions to Absorica LD.
Ilumya has been able to carve out a niche for itself in the fiercely competitive Psoriasis segment.
Ilumya, being a medical benefit product, does not directly compete with most drugs which fall into the pharmacy benefits segment.
Its new mechanism of action, fewer dosage, and low side effects also bode well for better uptake.
While Ilumya and Winlevi contribution can drive growth in specialty sales over the medium term, Sun Pharma has four products under clinical trials.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR